app slotbet Jacobs Stock Photography Ltd/DigitalVision via Getty Images Enphase ( NASDAQ: ENPH ) has seen a perfect storm sweep up its stock price. The company’s anticipated acceleration in growth rates has proven more modest as customers continue to adjust to the higher interest rate environment. The outcomes of the recent presidential elections Sign Up For My Premium Service "Best of Breed Growth Stocks" After a historic valuation reset, the growth investing landscape has changed. Get my best research at your fingertips today. Get access to Best of Breed Growth Stocks: My portfolio of the highest quality growth stocks. My best deep-dive investment reports. My investing strategy for the current market. and much more Subscribe to Best of Breed Growth Stocks Today! Julian Lin is a financial analyst. He finds undervalued companies with secular growth that appreciate over time. His approach is to look for companies with strong balance sheets and management teams in sectors with long growth runways. Best Of Breed Growth Stocks Learn more Analyst’s Disclosure: I/we have a beneficial long position in the shares of ENPH either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. I am long all positions in the Best of Breed Growth Stocks Portfolio. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.Ghana counts ballots after tight presidential race

Shadow of the Road - Official Gameplay Trailer Here's your look at gameplay from Shadow of the Road in this new trailer for the upcoming game that blends cRPG and turn-based strategy combat. The latest Shadow of the Road trailer gives us a peek at maps, combat, and formidable enemies, including a giant scorpion-type mech.In Shadow of the Road, explore the rich tapestry of an alternate 19th-century Japan as the Boshin War approaches a bitter and bloody end. Dive into in a world that combines tradition and modernity, Japanese mythology, and steampunk technology.

Trump chooses billionaire space tourist to run NASA

NEW YORK (AP) — U.S. stock indexes rose to more records Wednesday after tech companies talked up how much of a boost they’re getting from the artificial-intelligence boom. The S&P 500 climbed 0.6% to add to what’s set to be one of its best years of the millennium. It’s the 56th time the index has hit an all-time high this year after climbing in 11 of the last 12 days . The Dow Jones Industrial Average rose 308 points, or 0.7%, while the Nasdaq composite added 1.3% to its own record. Salesforce helped pull the market higher after delivering stronger revenue for the latest quarter than analysts expected, though its profit fell just short. CEO Mark Benioff highlighted the company’s artificial-intelligence offering for customers, saying “the rise of autonomous AI agents is revolutionizing global labor, reshaping how industries operate and scale.” The stock price of the company, which helps businesses manage their customers, jumped 11%. Marvell Technology leaped even more after delivering better results than expected, up 23.2%. CEO Matt Murphy said the semiconductor supplier is seeing strong demand from AI and gave a forecast for profit in the upcoming quarter that topped analysts’ expectations. All the optimistic talk helped Nvidia , the company whose chips are powering much of the move into AI, rally 3.5%. It was the strongest force pushing upward on the S&P 500 by far. They helped offset an 8.9% drop for Foot Locker, which reported profit and revenue that fell short of analysts’ expectations. CEO Mary Dillon said the company is taking a more cautious view, and it cut its forecasts for sales and profit this year. Dillon pointed to how keen customers are for discounts and how soft demand has been outside of Thanksgiving week and other key selling periods. Retailers overall have offered mixed signals about how resilient U.S. shoppers can remain. Their spending has been one of the main reasons the U.S. economy has avoided a recession that earlier seemed inevitable after the Federal Reserve hiked interest rates to crush inflation. But shoppers are now contending with still-high prices and a slowing job market . This week’s highlight for Wall Street will be Friday’s jobs report from the U.S. government, which will show how many people employers hired and fired last month. A narrower report released Wednesday morning suggested employers in the private sector increased their payrolls by less last month than economists expected. Hiring in manufacturing was the weakest since the spring, according to Nela Richardson, chief economist at ADP. The report strengthened traders’ expectations that the Fed will cut its main interest rate again when it meets in two weeks. The Fed began easing its main interest rate from a two-decade high in September, hoping to offer more support for the job market. The central bank had appeared set to continue cutting rates into next year, but the election of Donald Trump has scrambled Wall Street’s expectations somewhat. Trump’s preference for higher tariffs and other policies could lead to higher inflation , which could alter the Fed’s plans . Fed Chair Jerome Powell said Wednesday that the central bank can afford to cut rates cautiously because inflation has slowed from its peak two years ago and the economy remains sturdy. A separate report on Wednesday said health care, finance and other businesses in the U.S. services sector are continuing to grow, but not by as much as before and not by as much as economists expected. One respondent from the construction industry told the survey from the Institute for Supply Management that the Fed’s rate cuts haven't pulled down mortgage rates as much as hoped. Plus, “the unknown effect of tariffs clouds the future.” In the bond market, the yield on the 10-year Treasury fell to 4.18% from 4.23% late Tuesday. On Wall Street, Campbell’s sank 6.2% for one of the S&P 500’s sharper losses despite increasing its dividend and reporting a stronger profit than analysts expected. Its revenue fell short of Wall Street’s expectations, and the National Football League’s Washington Commanders hired Campbell’s CEO Mark Clouse as its team president. Gains for airline stocks helped offset that drop after JetBlue Airways said it saw stronger bookings for travel in November and December following the presidential election. It also said it’s benefiting from lower fuel prices, as well as lower costs due to improved on-time performance. JetBlue jumped 8.3%, while Southwest Airlines climbed 3.5%. All told, the S&P 500 rose 36.61 points to 6,086.49. The Dow climbed 308.51 to 45,014.04, and the Nasdaq composite rallied 254.21 to 19,735.12. In stock markets abroad, South Korea’s Kospi sank 1.4% following a night full of drama in Seoul. President Yoon Suk Yeol was facing possible impeachment after he suddenly declared martial law on Tuesday night, prompting troops to surround the parliament. He revoked the martial law declaration six hours later. In the crypto market , bitcoin climbed near $99,000 after Trump said he would nominate Paul Atkins , a cryptocurrency advocate, to chair the Securities and Exchange Commission. AP Writers Matt Ott and Zimo Zhong contributed.Nike Inc. Cl B stock rises Wednesday, outperforms market

France faces political turmoil as confidence vote topples PM Barnier's govtJimmy Carter, 39th U.S. president, Nobel winner, dies at 100

The UK and Qatar have launched a joint Artificial Intelligence (AI) research commission, seeking to establish a roadmap for UK-Qatar collaboration on AI that will benefit both countries, a statement from the British embassy in Doha said. The joint study will be led by Queen Mary University of London (QMUL), in partnership with Hamad bin Khalifa University (HBKU) in Qatar. The study is being led by Prof David Leslie, Professor of Ethics, Technology, and Society at QMUL’s Digital Environment Research Institute, and the director of Ethics and Responsible Innovation Research at the Alan Turing Institute. The project will build on the progress that both countries have made on AI, and identify and scope practical and ambitious ways for the countries to enhance their co-operation in this field in line with their AI and technology strategies. A range of areas will be explored across the spectrum of ecosystem development, policy and regulation, security, and international engagement. It been designed and developed as a collaboration between Qatar’s Ministry of Foreign Affairs (MoFA), the AI Committee of the Ministry of Communications & Information Technology (MCIT), Qatar Research, Development and Innovation Council (QRDI), and the British embassy in Qatar. The announcement of the collaboration coincides with the state visit of His Highness the Amir Sheikh Tamim bin Hamad al-Thani to the UK. The project is funded by the UK Government’s Gulf Strategy Fund, part of the Foreign, Commonwealth & Development Office’s International Programme. Neerav Patel, British ambassador to Qatar, said: “The UK and Qatar have shown themselves to be innovators in the policy implementation of AI, including the need to build strong systems of ethics and governance. I’m delighted that such prestigious UK and Qatari institutions are involved in this important initiative. It reflects both countries’ desire to work together on the shared challenges the 21st century will bring.” Dr Mariam Khalid al-Hamar, Minister Plenipotentiary at the MoFA in Qatar, said: “This initiative marks a key opportunity to advance innovation through collaboration. As a global leader in dialogue and mediation, Qatar recognises the vital importance of collaboration in promoting diplomacy and resolving conflicts. By leveraging the transformative potential of AI, we have the opportunity to make meaningful progress in peacebuilding, improve decision-making processes, and tackle complex global issues with greater accuracy. Furthermore, embracing the idea of 'AI for All' ensures that the benefits of this technology reach every nation, empowering them to actively engage in the AI era. This vision reflects our unwavering commitment to innovation, inclusivity, and ensuring that technology serves as a tool for justice and progress for all.” Eman Alkuwari, digital Innovation director from Qatar’s MCIT, said: “This collaboration marks a significant step forward in Qatar's commitment to advancing AI as a transformative force for good. By partnering with the UK and leveraging the expertise of world-renowned institutions, we aim to unlock new opportunities for innovation, shape ethical frameworks, and contribute to global progress in AI. This initiative reflects our shared vision to harness the power of technology for the benefit of our societies and economies.” Prof Leslie said: “By leveraging the dynamic AI research and innovation ecosystems of both nations, this initiative promises to be a catalyst for ingenuity and commercial opportunity, fostering a new era of technological co-operation between two global leaders in the field.” Omar al-Ansari, secretary general of QRDI, said: “This initiative marks a key opportunity to advance innovation through strategic collaboration in AI. By leveraging Qatar and the UK’s significant investments in AI research, development & innovation, we are paving the way for funding transformative projects. This partnership will strengthen the ties between Qatar and the UK’s innovation ecosystems, fostering the exchange of expertise and driving impactful outcomes for both nations.” Prof Colin Bailey, president and principal of QMUL, said: “We are proud and honoured to be embarking on this collaboration with Hamad bin Khalifa University in Qatar. Queen Mary University has a long history of building strong, successful international collaborations, and of being at the forefront of emerging research and technology. This new partnership will allow both universities to combine their collective knowledge and strengths to ensure AI technology is used in the best, safest way possible.”

Wisekey’S Subsidiary SEALCOIN 2025 Roadmap: Leading Machine-To-Machine Transactions Through Blockchain And Space InnovationNonePROVIDENCE, R.I. – The campus of Butler Hospital is awash in fall colors as the sun moves toward the horizon, on Thursday afternoon, Nov. 7. The shift of nurses, doctors and patients is on the move, the daily changing of the caretakers, as ConvergenceRI struggled on trekking poles to reach the main entrance, on time for an interview with Dr. Linda Carpenter, M.D. One of the pioneering neuroscience researchers at Butler Hospital, Dr. Carpenter is the lead clinical trial researcher on a new, take-home device (Relivion) created by Neurolief to treat major depressive disorder, a chronic and recurring condition that afflicts millions. The interview took place in Dr. Carpenter’s office at Butler Hospital, a portal into a space defined by stylish design and acute attention to detail. Dr. Carpenter is wearing a turquoise scarf that depicts the brain’s synapse structure, replete with dendrites and axons depicted in black. Two days before the interview, former President Donald Trump had been elected the 47th President of the United States, as if the entire nation had been victimized by a mass psychosis where facts no longer seemed to matter. That evening, members of the Rhode Island Senate would convene in a caucus that replicated a medical intervention, as Senators endorsed the continued leadership of Senate President Dominick Ruggerio, despite indications that his chronic health conditions had taken a severe toll. Earlier this summer, ConvergenceRI had conducted an interview with Dr. Carpenter, “Listening to what your brain is telling you,” following her being awarded the Clinical Transcranial Magnetic Stimulation Society Gold Medal. Dr. Carpenter serves as director of the Transcranial Magnetic Stimulation Clinic and Neuromodulation Research Facility at Butler Hospital, a division of Care New England. ConvergenceRI: I am amazed at the latest work, which seems to be just remarkable, in terms of its groundbreaking nature of treatment: The idea that people can have a take-home device that can help them with their treatment of drug-resistant depression. The treatment moves forward in such a way that it may help patients to overcome everything from long-term depression to migraines. CARPENTER: Right. The particular device that we are talking about today which is the subject of clinical trial that we just finished, is the same device that they have already gotten approved for migraines, but the stimulation pattern that it gives for depression is different. You would use this device [taking off her glasses to put on the device to model it], they may look the same, but the stimulation of the prescription , if you will, would be different for migraine than it is for depression. But, it is incredibly exciting, because we don’t yet have any FDA-approved home-use devices for depression. ConvergenceRI: My first question to you is, “How would I be able to get one of these devices?” How would I qualify? Are the clinical trials’ hurdle now over? CARPENTER: The clinical trial was conducted at multiple sites around the country, and I think we also had an Israeli site [the Relivion corporate headquarters are based in Israel with a facility in Florida]. The clinical trial proved the efficacy [of the device] by randomizing people in active or sham, right? The data demonstrated a superior outcome for the people who had active [devices]. At this point, the whole package of results has gone to the FDA, maybe about a month ago. And, they are processing it. Before the FDA started this trial, they gave this company what is known as a “breakthrough designation,” to help them get onto a fast track for going through the regulatory process, because they identified a need for patients with treatment-resistant depression to have [access to a device] at home. Many of [the patients] can’t come to our clinic five days a week for TMS [transcranial modulation stimulation], or they can’t come in for ECT [electro-convulsive therapy]; you would have to have someone drive [the patient] here and then drive them home. The FDA identified the need and put [the firm] on fast track. The company expects, and I don’t work for the company, but I think they expect to receive FDA approval in early 2025. And then, when that happens, they can commercially market the device. Now, how will that work? I don’t know. This is the first of its type, There are a couple different of ways that this can go. It could be that you come to your doctor’s office, they supervise you using it a couple of times until they are confident that you can use it properly. And then you take home the device, use it, come back, check in every two or three or four weeks, something like that. There is also this question of durable medical equipment, which is out of my wheelhouse and how it would work. Which is where you are a clinic and you actually sell the device to the patient. You have a stock of them. I don’t know what the business model will look like. What I do know is that it’s a prescription device . So, you will have to be monitored by a doctor. It doesn’t mean that it has to be a psychiatrist. You could go to a primary care doctor. But, when it first rolls out, because it is FDA-approved for people who have not gotten better with at least one anti-depressant medication, it will b prescribed typically by a psychiatrist at first, I think. And as broadly as it can be disseminated, that would be great. Because the goal would be to reach all of those patients who can’t come to a specialty clinic. And there are a lot of those. If you think about, when we talk about treatment resistant depression, basically about a third of patients don’t get better with standard anti-depressant treatment. And, that’ a huge number; it’s millions of patients, [looking it up on her computer]. There are some 21 million patients with depression, 9 million being treated with anti-depressants, and 3 million meet this criteria for treatment resistant depression if they don’t get better with a standard anti-depressant. We are looking to find and implement a treatment that would be more convenient and accessible – and I am very excited about that. ConvergenceRI: For me as the journalist, the question is: How could I get one of these devices and write about it, and perhaps become part of the follow-up. The goal would be, that as much as a scientific endeavor, I think that for people to understand what is going on, it might be helpful to have a journalist who can write about the experience and share that... CARPENTER: ...It would be fantastic. ConvergenceRI: ...in a comprehensive fashion, I am willing to raise my hand... CARPENTER: ...And volunteer? ConvergenceRI: I would volunteer to become a patient, or whatever is required, to do this, because I think for all the studies you can do, having someone to actually talk about it in a cogent fashion is intriguing to me. CARPENTER : Yes. You can go onto the company’s website and get a prescription for the migraine device. And, I don’t how you do that, I just noticed this (Relivion website for migraine) today, and I think you can purchase it and have it sent to you, and it would be very similar. You would get the experience of what it is like; they have a prescription and then there are accessories. ConvergenceRI: Would that come from through my primary care physician? CARPENTER: I was just looking to see if you could get a prescription under the migraine indication. The trial would go on for 60 days. This is a brand new website, (there is a listing, “Getting started. Telehealth and find a doctor.”) You might b able to interact with this website and get one for a migraine, with a telehealth physician. It looks like they give you ways to do that. ConvergnceRI: I will consider following up with that. From what you have described, it seems like it is a major breakthrough in treatment, with the possibility that this device will be something that will change the way that depression is treated. And perhaps conditions that are linked to depression, such as obsessive compulsive behavior. CARPENTER: Well, we haven’t tested those other indications. But I think you have the right idea. And, in fact, here are a number of devices, if you just Google them, you can find them. But the difference between this and those [other devices] is that they haven’t been put through large, randomized control trials, which takes a lot of time and a lot of money. ConvergenceRI: Have you gone through Phase I, Phase II, and Phase III clinical trials? CARPENTER: The clinical trials design are not the same for drugs as they are for devices. This would be a device that they tested it in an early pilot study. And, they have done all their safety testing before they came to this clinical trial. And, then, I guess, after FDA approval, this is all that will likely be needed according to the FDA to get the clearance. And then, after the clearance, there will be a lot of questions we need to address. We studied this, with people using it every day, active or sham, for a period of eight weeks. And then, what happened in this clinical trial, at the end of eight weeks, you got to crossover and go to active, if you had gotten the sham, and if you had already got active for eight weeks, you could, continue with eight more weeks of active. There were a number of questions built into [the study]. One, if you aren’t all the way better by eight weeks, and you keep going, will you get more people into remission? And, the answer to that question was yes, because more people kept getting better. And the other question was: If you had sham for the first eight weeks, and now you get the real device, can you replicate that the same percent of people were getting better, and we did. But some of the questions we haven’t answered are: OK, we’ve had people using the device for up to 16 weeks, what does the maintenance look like? Do you stop using it? Do you continue to use it? Do you continue to use it less often? How long will it last? Is it something that you are going to pick up when you start to slip and your [depressive] symptoms start to come up again? As soon as the FDA approval happens, then those will be next types of studies that we are doing. And also, we will be doing more mechanism of action studies. To do scans, before and after treatment, to look at how is it changing connections in the brain, and the way it does. ConvergenceRI: How has it changed your life? You have spent a large amount of time working on this, to see it come to creation. To now have a device that is sitting on front of you on your desk, and it seems to work, what is that like for you as a researcher, as a neuroscientist? CARPENTER: It is really exciting. I am very big on “the bench to bedside.” Getting all the way to implementation is something that I really, really enjoy. You know, a few of the hurdles that lay ahead are that this is a small, start-up company that is looking for a big company such as Pfizer to buy them and co-license it to help facilitate the next bunch of clinical trials that need to happen to answer all these additional questions. A lot of this is now in the hands of the device manufacturer, to take the next big steps to help get the device out there. I’m thrilled to be able to talk about it. I am thrilled to know that it works and to recommend it. But, access is so important. And, like all these other new treatments, if people can’t afford them, if health insurance doesn’t cover it... There needs to be access. I am just really hopeful that the pieces fall into place and that they are taken care of, because that is not [the focus of] my work. My work is the scientific work. To get it to implementation, so I can see patients using it. And not just in my clinical trials. We want people to be able to be use it; I think that will take some time. To answer your question directly, there is a little bit of antsy-ness about wanting to keep moving forward, and doing the next thing, to get their money and to get their companies and their commercial model all built. But, it’s exciting. It’s exciting to have been a part of designing the trial to help pick the sites, and make sure that it was conducted with scientific rigor. And to have good data. Because, you know, there are a number of devices out there. Congess passed a law in 1972 that said the FDA will regulate medical devices. And, ever since then, all the biomedical devices go through FDA. But, there were a bunch of devices on the market before 1972. And they were grandfathered in. They have been able to market themselves legally, without ever doing clinical trials, So there are all these devices that patients can get that they advertise for depression or for anxiety or pain, or to improve your dreaming, or something. But they just don’t have the science behind them. Psychiatrists and other physicians tend not to prescribe them; patients sometimes find them and ask, “Will you sign this form I got online?” But they haven’t really been incorporated into the mainstream of treatment because they haven’t had the science. So now, we have the first one with the science. And that is really exciting. I would like to see it become used as a regular treatment for depression. ConvergenceRI: What does it feel like for you to be able to help direct the first of its kind device with the promise of something to be so helpful to people, who are often struggling to get by day-today? CARPENTER: It feels great. It feels really great. We all want to do something, you work with patients, and you are experiencing their suffering, and the disabling nature of the depression. And, the problems with side effects. And, the burdens on families and the economy. It feels great to have something. It will feel greater when I can go, here you are. There are so many people who were involved with the device. I didn’t design it; I didn’t invent it. And, the company did really elegant work in putting it together. It has a really elegant interaction with your smart phone that walks you through how to use it, that checks to make sure that the device is on right, and that sends the information to the cloud that I can look at on a dashboard to see if the patient is using the device safely. But, you know, we are not completely at the finish line until it is disseminated. ConvergenceRI: Let me go back and ask about what is actually happening in the brain with the device. And please correct me if I get this wrong. The idea is what you are working with is the way that the brain can reconfigure the way that the synapses and the neurons fire, essentially that there is a learned pattern that takes place, so if you fire the sequence enough times, it becomes the learned pattern in the brain, and it doesn’t go back to all of the intermediate steps. It goes from A to F, without having gone through B, C, D, and E to get to F. What the device seems to be doing is retraining , if that is the right “verb” to use, to get the neurons to fire differently. CARPENTER: Right. ConvergenceRI: To take the “memories” that are contained, if “memory” is the right word, of what gets lost in the translation of the firing of the synapse. Is that accurate? CARPENTER: That’s a good way to think about it. Think about it like a computer. The computer has all these different parts that have to interact and, if one part breaks down, then the other parts might go around that part. This part might have the control of that part, like a circuit board. Think of depression like a circuit board. And just like you said, A, B, C, and D. And the circuits are connected by synapses, neurons and synapses, right? And so, like you said, if the part of the reward center and joy is turned off and not coming on, and the fear center and anxiety is on when it shouldn’t be, and the top control isn’t telling the others this isn’t the time to be anxious. This isn’t the time to be turned off, this isn’t the time to be attending – all those different signals. So, we know that there are these functional changes in the brain when someone is depressed. And, by and large, you can see when people get better, although depression has a lot of different versions, right? There are a lot of different versions of depression. If you look at all the different symptoms, and there are lot of different ways that it can look. But, in general, if you think about circuit pathology , that the circuit Is not working properly... ConvergenceRI: Circuit pathology? CARPENTER: Yes. Again, if I have a lot of anxiety in my depression, then my amygdala, its connections to other things are not being regulated. We want our brain to say, “Oh yes, be fearful,” when it is appropriate to be fearful, when you are in a terribly dangerous situation. But not when you are trying to relax, and your reward center should be able to turn on when you experience certain things. And so, negative old memories should stay put, and not come in and re-evaluate what is happening in the present, The question of how the device’s treatment for depression works to fix that is unanswerable. How does psychotherapy fix that? How does ECT fix that? How does medication fix that? What we know is where the device has its actions. Or where EMS has its actions. Or what Prozac sticks to on the molecule, right? And what we know about this device is that it stimulates some peripheral nerves, branches of nerves called the trigeminal nerve in the front and branches of these nerves in the back, and these are right underneath your skin, these nerves are stimulated in this synchronous way, carrying messages down to the brain stem. And, this goes up through a bunch of connections, the solitary tech nucleus, the hypothalamus, and gets into the nodes, as you will, of the circuit. How that fixes the regulation is the question. ConvergenceRI: Am I asking the right questions? CARPENTER: Oh, yes, I think they are great questions. ConvergenceRI: Thanks. Trying to translate what you are saying into language that people can understand, that’s part of the problem. I think I get some of it. But I am very much in awe of what it takes to translate what is happening, and the way that you then see it. There is clearly a difference between causation and correlation. CARPENTER: Just think about Prozac’s impact on the serotonin uptake inhibitors And people said: It sticks on this little thing on the cell and it causes more serotonin to be in the cell. It’s not like we’re all down a quart of serotonin; it still is changing the circuits and how they talk to each other. And sometimes, we act like we know exactly how a treatment works. How does psychotherapy work? And that is really a retraining right? Forcefully creating new habits. ConvergenceRI: How tied into other senses is this work? With psychotherapy, you have to listen. In terms of drug intake, it is all about modulating how we respond to pleasure, versus things that are not pleasurable, and the wirings that enable that to happen. CARPENTER: That’s the black box, the wiring that enables it to happen. So, that when a pleasant thing happens, joy, dopamine, the reward circuit is firing. You see your grandchild, you see your friend. You have a good thing happen. The common bottom line seems to be getting all those different functional areas of the brain to coordinate properly, particularly with top-down control, turning off things that are not appropriate and allowing things that are. When reward circuits are down, people feel apathetic, they feel no interest in things, no drive to pursue things. The last step is making the symptoms go away. Each of the treatments we talked about has a different way of approaching it.

A look back at 2024 in photosAhead of unveiling, new T’gana statue design triggers slugfest

Vivek Vishwakarma The recent stagnation in REIT valuations creates an opportunity for income investors to layer in capital at attractive prices. While it’s tempting to add to well-recognized names like Realty Income ( O ) and W.P. Carey ( Read The Full Report on iREIT+Hoya iREIT+HOYA Capital is the premier income-focused investing service on Seeking Alpha. Our focus is on income-producing asset classes that offer the opportunity for sustainable portfolio income , diversification , and inflation hedging . Get started with a Free Two-Week Trial and take a look at our top ideas across our exclusive income-focused portfolios. With a focus on REITs, ETFs, Preferreds, and 'Dividend Champions' across asset classes, members gain complete access to our research and our suite of trackers and portfolios targeting premium dividend yields up to 10%. I am Gen Alpha. I have more than 14 years of investment experience, and an MBA in Finance. I focus on stocks that are more defensive in nature, with a medium- to long-term horizon. I provide high-yield, dividend growth investment ideas in the investing group iREIT®+HOYA Capital . The group helps investors achieve dependable monthly income, portfolio diversification, and inflation hedging. It provides investment research on REITs, ETFs, closed-end funds, preferreds, and dividend champions across asset classes. It offers income-focused portfolios targeting dividend yields up to 10%. Learn more . Analyst’s Disclosure: I/we have a beneficial long position in the shares of NLCP either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. I am not an investment advisor. This article is for informational purposes and does not constitute as financial advice. Readers are encouraged and expected to perform due diligence and draw their own conclusions prior to making any investment decisions. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.The Rick Campbell era has ended while the Ryan Rigmaiden era has begun. The B.C. Lions introduced Rigmaiden as the football club’s new general manager at a press conference at the team’s Surrey practice facility on Wednesday, and at the same time, announced that they had parted ways with head coach Rick Campbell after four seasons and that Neil McEvoy was moving from the co-GM position that he shared with Campbell to the newly-created title of Vice President of Football Operations. As we speculated last week in this column , the club moved quickly to elevate Rigmaiden from his previous role of Assistant General Manager and Director of U.S. Scouting in an effort to retain the 45-year-old native of Spokane, Washington. Rigmaiden was the Lions Director of U.S. Scouting from 2013 to 2017 before leaving to join the Winnipeg Blue Bombers organization. He returned in 2020 and has been responsible for bringing in import talent such as Sione Teuhema, Josh Banks, Alexander Hollins, Manny Rugamba, Jarell Broxton, Josh Woods and Kent Perkins to the Lions. His first task as general manager will be to find a new head coach. “The head coaching search is going to start immediately. There are several coaches that are currently unemployed that we are going to talk to. We also have several here internally that we will interview as well and then get permission (from other teams) for a handful of others,” said Rigmaiden, who becomes the 17th general manager in club history. There are approximately “eight to 10” candidates that the club will interview via ZOOM calls over the next week to 10 days, with that number being whittled down to three or four finalists who will then be interviewed in person. The front-runner for the head coaching position is former Lions quarterback Buck Pierce, who has been with the Winnipeg Blue Bombers organization since 2014 in various coaching capacities and has held the title of offensive coordinator since 2020. Other candidates include former Hamilton head coach Orlondo Steinauer, former Winnipeg and Ottawa head coach Paul LaPolice, former B.C. and Hamilton defensive coordinator Mark Washington and former Calgary special teams coordinator Mark Kilam as well as internal candidates that include offensive coordinator Jordan Maksymic and defensive coordinator Ryan Phillips, who is the only assistant from last year’s staff still under contract. The organization has no timeline in terms of naming a head coach and both Rigmaiden and McEvoy stressed that this will not be a rushed decision. That being said, there has to be some urgency as the new head coach will need time to assemble his own staff moving forward. Rigmaiden has set out three criteria that his hire will have to meet. “Leadership, accountability and toughness. I think those are essential for any head coach no matter what sport you are talking about. That’s going to be something that we emphasize,” replied Rigmaiden when queried on the subject. Rigmaiden hopes the new coach will be able to get the Lions to play with some edge. “The biggest thing I see is our lack of ability to overcome adversity on the field. There is a lack of mental toughness on this team. Internally, we have all been discussing that after last season. There are a variety of reasons why that happens. Instilling a new head coach with some different ideas and different values is going to be the biggest part of that,” said Rigmaiden. Another pressing item on his agenda will be trading quarterback Vernon Adams Jr. and there has already been an organizational shift in philosophy in how that will be dealt with moving forward. “He (Adams Jr.) will not have a say in this process. We are going to do what’s best for the club but we are going to be in constant communication with him,” said Rigmaiden, walking back a promise that Campbell made as co-gm that Adams Jr. would be consulted in trade talks. Rigmaiden added that it was strictly a business call, referring to his solid relationship with Adams Jr. going back to the time when Adams Jr. was a 19-year-old at Eastern Washington University, and that the process would begin immediately by “calling two or three teams” on Monday night. EXTRA POINTS * The natural landing spot for Campbell is Edmonton. As we mentioned last week, new Edmonton owner Larry Thompson wants to reconnect the Elks to the history and tradition of the Eskimos. He already has hired Chris Morris as the Elks president and then followed that up by signing Ed Hervey as the Elks general manager. Morris played 14 years for the Eskimos while Hervey suited up for eight seasons with the green and gold. Hiring Campbell would be a natural fit seeing how his father Hugh coached the Eskimos to five straight Grey Cups from 1978 to 1982. Hervey also hired Campbell in B.C. during his stint as the Lions general manager. * As for the Lions assistant coaches, Phillips could be reunited with former teammate Dave Dickenson as the defensive coordinator for the Calgary Stampeders if things don’t work out in B.C. Meanwhile, Edmonton has asked the Lions for permission to speak to Maksymic about their head coaching vacancy. In other news, linebackers coach Travis Brown has interviewed for the defensive coordinators position in Ottawa but could follow Campbell to Edmonton if the Ottawa job falls through as the two have history together going back to Brown’s playing days as a RedBlack. * With Hervey leaving as Tiger-Cats general manager, former Lions quarterback Danny McManus becomes the leading candidate to replace him in Hamilton. McManus, who led the Leos to a Grey Cup in 1994, has been with Winnipeg since 2013 as the club’s assistant general manager and director of U.S. scouting. McManus was also the quarterback for Hamilton when they last won the Grey Cup in 1999 and is revered in The Hammer. Other candidates include former UBC head coach Ted Goveia, who is the Bombers assistant GM and director of player personnel and a pair of Canadians working as scouts in the NFL in Vince Magri (Buffalo) and Chris Rossetti (New York Giants). Magri and Rossetti both spent time with the Toronto organization before going south. Veteran B.C. sports personality Bob “the Moj” Marjanovich writes twice weekly for Black Press Media.

Jimmy Carter: Many evolutions for a centenarian ‘citizen of the world’

Inventus Mining (CVE:IVS) Shares Down 21.1% – Here’s WhyCHARLOTTE, N.C. (AP) — Quimari Peterson had 16 points in East Tennessee State's 75-55 win over Charlotte on Wednesday. Peterson had five rebounds for the Buccaneers (5-2). John Buggs III went 6 of 12 from the field (3 for 5 from 3-point range) to add 15 points. Karon Boyd shot 3 for 8 (1 for 3 from 3-point range) and 7 of 10 from the free-throw line to finish with 14 points, while adding seven rebounds. Jaehshon Thomas led the way for the 49ers (3-3) with 13 points. Charlotte also got 13 points from Nik Graves. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .

Radian Group CEO sells $699,156 in stock